SCHEMBL30516644

SCHEMBL30516644

COc1cc(F)cc(-c2ccc(CO)cn2)c1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 3/20 0.55
▸ LDHA P00338 1/20 0.47
▸ CYP11B1 P15538 5/20 0.43
▸ CYP11B2 P19099 3/20 0.43
▸ CASP3 P42574 1/20 0.43
▸ SENP8 Q96LD8 1/20 0.43
▸ SENP7 Q9BQF6 1/20 0.43
▸ SENP6 Q9GZR1 1/20 0.43
▸ CBFB Q13951 2/20 0.43
▸ FYN P06241 3/20 0.42
▸ GRM5 P41594 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ CYP1A1 P04798 1/20 0.38
▸ CYP1B1 Q16678 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25367014 1.00 KDM1A (0.55) KDM1ALDHACYP11B1CYP11B2CASP3
SCHEMBL15349769 0.83 CBFB (0.48) KDM1ALDHACYP11B1CYP11B2CASP3
SCHEMBL24784608 0.81 KDM1A (0.40) KDM1ALDHACYP11B1CYP11B2FYN
SCHEMBL8019903 0.79 CASP3 (0.64) KDM1ACYP11B1CYP11B2CASP3SENP8
SCHEMBL26784179 0.79 ABL1 (0.49) CASP3SENP8SENP7SENP6NPC1
SCHEMBL30103132 0.79 KDM1A (0.47) KDM1ALDHAGRM5NPC1RAB9A
SCHEMBL24785377 0.79 KDM1A (0.47) KDM1ALDHAGRM5NPC1RAB9A
SCHEMBL24453569 0.76 CASP3 (0.52) KDM1ACYP11B1CYP11B2CASP3SENP8
SCHEMBL4116531 0.75 BRAF (0.49) FYNNPC1RAB9A
SCHEMBL24785040 0.75 KDM1A (0.55) KDM1ACYP11B1CYP11B2CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119013017-A Pharmaceutical composition for treating cancer comprising an anticancer agent and a novel compound having an inhibitory activity on prostaglandin E2 receptor 治纳辅医药科技有限公司 2024-11-22 — — CN disclosed
WO-2023158221-A1 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS 주식회사 카나프테라퓨틱스 2023-08-24 — — WO disclosed
CN-116529238-A Novel prostaglandin E 2 Compounds with receptor inhibiting activity and uses thereof 治纳辅医药科技有限公司 2023-08-01 — — CN disclosed
Send feedback